MAYO CLINIC LABORATORIES

1-800-533-1710

# AD2

PrecivityAD2, Plasma

| Patient ID | Patient Name | | Birth Date | Sex | Age |
|---|---|---|---|---|---|
| SA00181773 | SAMPLEREPORT, AD2 | | 1984-05-01 | F | 42 |
| **Order Number** | **Client Order Number** | **Ordering Physician** | **Report Notes** | | |
| SA00181773 | SA00181773 | CLIENT,CLIENT | | | |
| **Account Information** | | **Collected** | | | |
| C7028846 DLMP Rochester | | 15 Oct 2026 04:04 | | | |

## PrecivityAD2

### Amyloid Probability Score

Y350

79

Abn

**Reference Value**
<27.5

### APS2 Result

Y350

Positive

### Interpretation

Y350

A Positive result is consistent with the presence of brain amyloid pathology. This result increases the likelihood that a patient's clinical presentation is due to Alzheimer's disease. The APS2 result alone does not establish a diagnosis of clinical Alzheimer's disease. Clinical correlation is recommended. Positive > 66.5 is consistent with brain amyloid pathology Likely Positive > 27.5 to < 66.5 is likely consistent with brain amyloid pathology Negative < 27.5 is not consistent with brain amyloid pathology

### Indication for Use of the Test

Y350

Alzheimer's disease (AD) is defined pathologically by the presence of amyloid plaques and neurofibrillary tangles in the brain. The PrecivityAD2(R) test is indicated for use in adults aged 40 years and older who present with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer's disease or other forms of cognitive decline, and is intended to be used in conjunction with clinical assessment to identify patients with amyloid pathology associated with AD.

### Test Description and Clinical Performance

Y350

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) following immunoprecipitation is utilized for quantification of concentrations of AD Core 1 biomarkers (Abeta42 and p-tau217) and their reference proteins (Abeta40 and np-tau217) for normalizing ratio calculations. A proprietary algorithm combines Abeta42/40 ratio and p-tau217/np-tau217 X 100 (%p-tau217) to generate the Amyloid Probability Score 2 (APS2), a numerical value ranging from 0–100, that determines whether a patient is Positive, Likely Positive or Negative for the presence of brain amyloid pathology. The clinical performance of this test was evaluated in a multi-cohort study of 1,142 patients presenting with subjective cognitive decline, mild cognitive impairment, or dementia. The test demonstrated high concordance with brain amyloid status as determined by amyloid PET (visual read) or CSF biomarker analysis: the positive predictive value (PPV) was 97.6% and negative predictive value (NPV) was 93.1% (at an overall brain amyloid positivity prevalence of 52.7%). For patients in the Likely Positive category, the PPV was 77.3%. The test demonstrated consistent diagnostic performance across patients regardless of their age, number of comorbidities (1,2,3+), or comorbidities studied including atrial fibrillation, autoimmune / inflammatory disease, chronic heart failure, chronic kidney disease, coronary heart disease, depression, diabetes, dyslipidemia, history of cancer, history of stroke / transient ischemic attack, hypertension, and obesity. This test has been cleared by the U.S. Food and Drug Administration (FDA).

### Limitations

Y350

Refer to product label at www.precivityad2.com for description of test limitations.

### Performing Site

Y350

C2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110–1–877-C2N-DIAG (226–3424) - CLIA license #26D2184292 CAP# 8488006 Laboratory Director: Kristopher Kirmess, PhD, HCLD (ABB) PrecivityAD2(R) is a registered trademark of C2N Diagnostics, LLC. (C) 2026 C2N Diagnostics, LLC. All Rights Reserved.

**Received:** 15 Oct 2026 08:08 **Reported:** 19 Oct 2026 17:26

**Performing Site Legend**

| Code | Laboratory | Address | Lab Director | CLIA Certificate |
|---|---|---|---|---|
| Y350 | C2N Diagnostics LLC | 4340 Duncan Avenue, St. Louis, MO 631101110 | | |